Brief: Celldex Therapeutics Says It Presents Positive 12 Week Results From Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria

Celldex Therapeutics

24/02/2024 19:07

Feb 24 (Reuters) - Celldex Therapeutics Inc  CLDX.O :
    * CELLDEX THERAPEUTICS PRESENTS POSITIVE 12 WEEK RESULTS
FROM
BARZOLVOLIMAB PHASE 2 STUDY IN CHRONIC SPONTANEOUS URTICARIA
    * 52 WEEK RESULTS AND PHASE 3 CSU TRIAL INITIATIONS
ANTICIPATED IN
2024
    * BARZOLVOLIMAB WAS WELL TOLERATED WITH A FAVORABLE SAFETY
PROFILE.
    * CELLDEX THERAPEUTICS- PRIMARY & SECONDARY ENDPOINTS MET
WITH
CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT DECREASES IN
URTICARIA DISEASE ACTIVITY

Source text for Eikon:  ID:nGNX77mPdc 
Further company coverage:  CLDX.O 

 ((Reuters.Briefs@thomsonreuters.com;))